Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aknemycin Plus Lösung is a topical combination therapy containing the macrolide antibiotic erythromycin and the retinoid tretinoin. It is indicated for the treatment of various forms of acne vulgaris, including both non-inflammatory comedonal acne and inflammatory papulopustular acne, particularly in patients with oily (seborrheic) skin. Erythromycin acts as an antibacterial agent that inhibits protein synthesis in acne-associated bacteria such as *Cutibacterium acnes*, thereby reducing bacterial colonization and local inflammation. Tretinoin, a vitamin A derivative, promotes skin cell turnover, decreases the cohesiveness of follicular epithelial cells, and facilitates the extrusion of comedones, preventing new blockages from forming. The formulation is delivered as a cutaneous solution with an integrated applicator pad, allowing for direct and hygienic application to the affected skin areas.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on erythromycin + tretinoin.